Affiliation:
1. National Clinical Research Center for Infectious Diseases Shenzhen Third People's Hospital Southern University of Science and Technology 29 Bulan Road Shenzhen Guangdong 518112 China
2. Center for Cellular and Molecular Diagnostics Tulane University School of Medicine 1430 Tulane Ave New Orleans LA 70112 USA
3. Department of Biochemistry and Molecular Biology Tulane University School of Medicine 1430 Tulane Ave New Orleans LA 70112 USA
4. Tolo Biotechnology Company Limited 333 Guiping Road Shanghai 200233 China
Abstract
AbstractNumerous groups have employed the special properties of CRISPR/Cas systems to develop platforms that have broad potential applications for sensitive and specific detection of nucleic acid (NA) targets. However, few of these approaches have progressed to commercial or clinical applications. This review summarizes the properties of known CRISPR/Cas systems and their applications, challenges associated with the development of such assays, and opportunities to improve their performance or address unmet assay needs using nano‐/micro‐technology platforms. These include rapid and efficient sample preparation, integrated single‐tube, amplification‐free, quantifiable, multiplex, and non‐NA assays. Finally, this review discusses the current outlook for such assays, including remaining barriers for clinical or point‐of‐care applications and their commercial development.
Funder
National Institutes of Health
U.S. Department of Defense
Subject
General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献